2008-02-20
The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands
Publication
Publication
Vaccine , Volume 26 - Issue 8 p. 1118- 1127
The objective of this study was to estimate the cost-utility of mass vaccination of 0-4-year-old children with Rotarix™ in the Netherlands. We used a Markov process with Dutch data on incidence, resource use and costs (GP, hospitalisation, productivity loss and household costs) to compare vaccination to conventional treatment from a societal perspective. Utility loss due to rotavirus-induced diarrhoea was measured using EQ5D, with GPs and paediatricians serving as proxies to fill out the questions. As the costs of a vaccination course ranged from €90 to €100 per child, the cost-utility ratio varied from €21,900 to €35,076 per QALY gained. Based on the current study, it is clear that mass vaccination with Rotarix™ against rotavirus gastroenteritis can be attractive, from an economic and a health care perspective.
| Additional Metadata | |
|---|---|
| , , | |
| doi.org/10.1016/j.vaccine.2007.11.070, hdl.handle.net/1765/29547 | |
| Vaccine | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Goossens, L., Standaert, B., Hartwig, N., Hövels, A., & Al, M. (2008). The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine, 26(8), 1118–1127. doi:10.1016/j.vaccine.2007.11.070 |
|